MX2022013753A - Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. - Google Patents

Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.

Info

Publication number
MX2022013753A
MX2022013753A MX2022013753A MX2022013753A MX2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A MX 2022013753 A MX2022013753 A MX 2022013753A
Authority
MX
Mexico
Prior art keywords
sup
treatment
amino acid
acid compounds
respiratory diseases
Prior art date
Application number
MX2022013753A
Other languages
English (en)
Inventor
Hui Li
Manuel Munoz
Katerina Leftheris
Eric Lefebvre
Lan Jiang
Chengguo Dong
Yajun Zheng
Jacob Cha
Timothy Hom
Jr David J Morgans
Maureen Reilly
Scott Turner
Kraig Anderson
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of MX2022013753A publication Critical patent/MX2022013753A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a métodos de terapia que usan compuestos de la Fórmula (I) y la Fórmula (II): (ver fórmula) o una sal del mismo, en donde R1 , R2 , R10, R11, R12, R13, R14, R 15, R16, q y p son como se describe en la presente. Los compuestos de la fórmula (II) y las composiciones farmacéuticas de los mismos son inhibidores de integrina que son útiles en la terapia para una condición, por ejemplo, provocada por o asociada con un agente infeccioso, shock, pancreatitis o trauma. La condición puede incluir una o más de fibrosis pulmonar asociada con artritis reumatoide o colestasis intrahepática familiar progresiva (PFIC).
MX2022013753A 2020-05-07 2021-04-30 Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. MX2022013753A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021674P 2020-05-07 2020-05-07
PCT/US2021/030363 WO2021225912A1 (en) 2020-05-07 2021-04-30 Treatment of respiratory diseases with amino acid compounds

Publications (1)

Publication Number Publication Date
MX2022013753A true MX2022013753A (es) 2023-01-30

Family

ID=78468277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013753A MX2022013753A (es) 2020-05-07 2021-04-30 Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.

Country Status (10)

Country Link
US (1) US20230181546A1 (es)
EP (1) EP4146264A4 (es)
JP (1) JP2023524970A (es)
KR (1) KR20230049584A (es)
CN (1) CN115989235A (es)
AU (1) AU2021268889A1 (es)
CA (1) CA3173761A1 (es)
IL (1) IL297969A (es)
MX (1) MX2022013753A (es)
WO (1) WO2021225912A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049068A1 (en) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
EP3558303A4 (en) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. AMINO ACID COMPOUNDS AND METHOD FOR USE
EP4328230A3 (en) 2018-03-07 2024-04-24 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
WO2020210404A1 (en) 2019-04-08 2020-10-15 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
CN116710169A (zh) 2020-11-19 2023-09-05 普利安特治疗公司 整合素抑制剂及其用途
WO2022232838A1 (en) * 2021-04-30 2022-11-03 Pliant Therapeutics, Inc. Expanded dosage regimens for integrin inhibitors
TW202408530A (zh) * 2022-07-09 2024-03-01 美商普萊恩醫療公司 整合素抑制劑及其與其他藥劑併用之用途
WO2024119067A1 (en) 2022-12-02 2024-06-06 Neumora Therapeutics, Inc. Methods of treating neurological disorders
WO2024125634A1 (zh) * 2022-12-16 2024-06-20 西藏海思科制药有限公司 一种四氢萘啶类化合物及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1504764E (pt) * 1997-08-08 2009-01-14 Univ California Tratamento da fibrose hepática com anticorpos contra integrina alfa-v-beta 6
DE10204789A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
EP4328230A3 (en) * 2018-03-07 2024-04-24 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EP3864041A2 (en) * 2018-10-09 2021-08-18 Medimmune, LLC Combinations of anti-staphylococcus aureus antibodies

Also Published As

Publication number Publication date
IL297969A (en) 2023-01-01
EP4146264A1 (en) 2023-03-15
EP4146264A4 (en) 2024-07-24
CN115989235A (zh) 2023-04-18
US20230181546A1 (en) 2023-06-15
CA3173761A1 (en) 2021-11-11
AU2021268889A1 (en) 2022-12-15
KR20230049584A (ko) 2023-04-13
JP2023524970A (ja) 2023-06-14
WO2021225912A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
MX2022013753A (es) Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.
CR20200452A (es) Compuestos de aminoacidos y métodos de uso
MX2022010011A (es) Inhibidores de prmt5 novedosos.
CR20210224A (es) Compuestos de amoniácidos y métodos de uso
MX2023007192A (es) Inhibidores de prmt5.
MX2020007944A (es) Nanocomplejos similares a los lípidos y sus usos.
CR20210041A (es) Compuestos de aminoácidos con ligadores no ramificados y métodos de uso
EA201991615A1 (ru) Композиция маннуроновой дикислоты
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
ECSP055595A (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
TW200639159A (en) Treatment of pain
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
NO20071314L (no) Peptidiske vasopressinreseptoragonister
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2021014115A (es) Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
PH12021550767A1 (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
MX2024004438A (es) Inhibidores de integrinas y usos de los mismos en combinacion con otros agentes.
CR20230143A (es) Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso
GEP201706609B (en) Composition for nasal application with improved stability
MX2023012794A (es) Regímenes de dosificación expandidos para inhibidores de integrina.